Resectable head and neck
ASCO recommends surgery and postoperative radiotherapy, including early stage disease.
ACC
Programs, trials, and reported response and survival for adenoid cystic carcinoma.
Standard of care
Resectable head and neck adenoid cystic carcinoma is principally managed with surgery and postoperative radiotherapy. Recurrent or metastatic disease has no universally preferred systemic regimen and no identified ACC specific FDA approved systemic therapy as of November 7, 2026. VEGFR tyrosine kinase inhibitors have activity but are off label. Named MYB directed and antibody drug conjugate programs in the review remain investigational.
NOT INVESTMENT ADVICE. This is a general evidence review, not individualized medical advice. A line is shown only when the cited review or a trial record in this file states it.
No drugs selected. The grid shows every stated option.
How to read a tile
An empty cell reads “No standard.” The words on the tile carry the status. Border style repeats it.
| Subgroup | Surgery | Radiotherapy | Observation | Systemic therapy |
|---|---|---|---|---|
| Resectable head and neckASCO recommends surgery and postoperative radiotherapy, including early stage disease. | No standard | No standard | ||
| UnresectableDefinitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial. | No standard | No standard | No standard | |
| Isolated local recurrenceThe review says reassess for salvage surgery, and that re irradiation belongs in an experienced center. | No standard | No standard | ||
| Recurrent or metastatic, asymptomatic slow growthMonitored observation can be appropriate for asymptomatic, slowly growing lung only disease. | No standard | No standard | No standard | |
| Recurrent or metastatic, symptoms or growthThe review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026. | No standard | No standard | No standard | Off label Lenvatinib Off label Axitinib Off label Axitinib plus avelumab Off label Cyclophosphamide, doxorubicin, and cisplatin Not established Pembrolizumab InvestigationalPhase 2 Rivoceranib InvestigationalPhase 1/2 REM-422 InvestigationalPhase 1 RGT-61159 InvestigationalPhase 1/2 Emiltatug ledadotin InvestigationalPhase 2 Osugacestat InvestigationalPhase 2 Regorafenib |
| Labeled biomarker presentA tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval. | No standard | No standard | No standard |
ASCO recommends surgery and postoperative radiotherapy, including early stage disease.
Definitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial.
No standard
The review says reassess for salvage surgery, and that re irradiation belongs in an experienced center.
Monitored observation can be appropriate for asymptomatic, slowly growing lung only disease.
No standard
The review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026.
No standard
A tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval.
No standard
ASCO recommends surgery and postoperative radiotherapy, including early stage disease.
Definitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial.
The review says reassess for salvage surgery, and that re irradiation belongs in an experienced center.
Monitored observation can be appropriate for asymptomatic, slowly growing lung only disease.
No standard
The review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026.
No standard
A tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval.
No standard
ASCO recommends surgery and postoperative radiotherapy, including early stage disease.
No standard
Definitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial.
No standard
The review says reassess for salvage surgery, and that re irradiation belongs in an experienced center.
No standard
Monitored observation can be appropriate for asymptomatic, slowly growing lung only disease.
The review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026.
No standard
A tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval.
No standard
ASCO recommends surgery and postoperative radiotherapy, including early stage disease.
No standard
Definitive radiotherapy is described when surgery is not feasible. Routine concurrent chemotherapy is not recommended outside a trial.
No standard
The review says reassess for salvage surgery, and that re irradiation belongs in an experienced center.
No standard
Monitored observation can be appropriate for asymptomatic, slowly growing lung only disease.
No standard
The review finds no universally preferred systemic regimen and no ACC specific FDA approved systemic therapy as of November 7, 2026.
Off label
Lenvatinib
Off label
Axitinib
Off label
Axitinib plus avelumab
Off label
Cyclophosphamide, doxorubicin, and cisplatin
Not established
Pembrolizumab
InvestigationalPhase 2
Rivoceranib
InvestigationalPhase 1/2
REM-422
InvestigationalPhase 1
RGT-61159
InvestigationalPhase 1/2
Emiltatug ledadotin
InvestigationalPhase 2
Osugacestat
InvestigationalPhase 2
Regorafenib
A tissue agnostic label applies only when the ACC meets that label. It is not a general ACC approval.